Top Tweets for #ACLC22

over 3 years ago

During #ACLC22, Yoshihisa Matsumoto, MD, PhD, discussed cancer pain management guidelines and the importance of individualized assessments. Read a recap in ILCN: https://t.co/wPYAQRaDgJ #LCSM

0

3

1

986

over 3 years ago

At #ACLC22, David Hui, MD, MSc, discussed how palliative care has evolved to emphasize earlier supportive care for patients with #lungcancer. Read more in ILCN: https://t.co/z5pIMnKwK7 #LCSM

0

18

2

0

over 3 years ago

During #ACLC22, Gee-Chen Chang MD, PhD, addressed the rising global threat of #lungcancer in patients who have never smoked. Read a recap in ILCN: https://t.co/r6c1kr6GG1 #LCSM

0

12

5

1

0

over 3 years ago

In this episode, @StephenVLiu discusses the #ACLC22 & #ESMO22 meetings w/guests Dr. James Yang (National Taiwan University Hospital), @reungwetwattana (@Ramathibodi & @MahidolU), & Dr. Takashi Setothor (National Kyushu Cancer Center). Listen: https://t.co/KUq321rUo7 #LCSM

IASLC's tweet photo. In this episode, @StephenVLiu discusses the #ACLC22 & #ESMO22 meetings w/guests Dr. James Yang (National Taiwan University Hospital), @reungwetwattana (@Ramathibodi & @MahidolU), & Dr. Takashi Setothor (National Kyushu Cancer Center). Listen: https://t.co/KUq321rUo7 #LCSM https://t.co/65CugQlknm

0

9

4

0

Stephen V Liu, MD

@StephenVLiu

over 3 years ago

Highlights from ESMO Asia and the @IASLC Asia Conference on Lung Cancer in tomorrow's episode of #LungCancerConsidered, the official IASLC podcast with guests Drs. @reungwetwattana @TakashiSeto3 and James Yang! #ESMOAsia22 #ACLC22 #LCSM

StephenVLiu's tweet photo. Highlights from ESMO Asia and the @IASLC Asia Conference on Lung Cancer in tomorrow's episode of #LungCancerConsidered, the official IASLC podcast with guests Drs. @reungwetwattana @TakashiSeto3 and James Yang! #ESMOAsia22 #ACLC22 #LCSM https://t.co/H8xfPEWNOl

0

23

3

1

0

over 3 years ago

During #ACLC22, @NReguart reviewed the latest treatment options for MET-dysregulated #NSCLC. Read a recap in ILCN: https://t.co/YWEIuuhdzH #LCSM

0

14

6

1

0

Amy C. Cavers

@cavemom11

almost 4 years ago · Phoenix

Thank u @IASLC - Asian Lung #ACLC22 in beautiful Nara, Japan. Data, interactions & culture into #LCAM22. NRG1 by James Chih-Hsin Yang Taiwan & @MNagasaka UC- I. Did I mention how hard it is to get a good selfie w/ a deer? #LCAM22 #NRG1 #NSCLC #CRESTONE @HwakeleeMD @karenkellymd

cavemom11's tweet photo. Thank u @IASLC - Asian Lung #ACLC22 in beautiful Nara, Japan. Data, interactions & culture into #LCAM22. NRG1 by James Chih-Hsin Yang Taiwan & @MNagasaka UC- I. Did I mention how hard it is to get a good selfie w/ a deer? #LCAM22 #NRG1 #NSCLC #CRESTONE @HwakeleeMD @karenkellymd https://t.co/aPIFkhzJnR

0

4

0

Amy C. Cavers

@cavemom11

almost 4 years ago · Phoenix

Along with lung cancer awareness month #LCAM22 data was presented at @IASLC #ACLC22 for rare #NRG1 gene fusions found with RNA based seq comprehensive genomic or Biomarker testing.

Wonyoung Jung, MD,PhD,MSc @DrJung_FM

almost 4 years ago

@MNagasaka presented the initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions (CRESTONE). #ACLC22 @IASLC #LCSM

HHorinouchi's tweet photo. @MNagasaka presented the initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions (CRESTONE). #ACLC22 @IASLC #LCSM https://t.co/xcD68FLQZ6

0

10

3

2

0

10

1

0

Triparna Sen (Sen-Lab)

@triparnasen

almost 4 years ago · Manhattan

I love, love, love research! Not just because it challenges you daily, also because it makes you meet wonderful people & places. @HwakeleeMD @t_mitsudomi @karenkellymd @HHorinouchi #lungcancer @IASLC #ACLC22 #SCLC

triparnasen's tweet photo. I love, love, love research!
Not just because it challenges you daily, also because it makes you meet wonderful people & places.
@HwakeleeMD @t_mitsudomi @karenkellymd @HHorinouchi #lungcancer @IASLC #ACLC22 #SCLC https://t.co/t7CT1B9ggJ

0

6

0

almost 4 years ago

So honored to be selected as a winner for education award @IASLC #ACLC22 (My first attending international conference!)

0

1

0

Anne Tsao, MD, MBA

@AnneTsao2

almost 4 years ago

Honored to have been invited to present at #ACLC22 on this important topic! We need more investment in cancer research! #EndCancer

almost 4 years ago

Dr. Anne Tsao of @MDAndersonNews presents Biomarkers & Novel Therapeutics in #Mesothelioma at #ACLC22. She outlines more about #biomarkers, mutations, frontline therapies that may change SOC, & salvage therapies, including novel agents under investigation.

IASLC's tweet photo. Dr. Anne Tsao of @MDAndersonNews presents Biomarkers & Novel Therapeutics in #Mesothelioma at #ACLC22. She outlines more about #biomarkers, mutations, frontline therapies that may change SOC, & salvage therapies, including novel agents under investigation. https://t.co/cZEEa5Z5tb

0

11

1

2

0

11

4

0

Triparna Sen (Sen-Lab)

@triparnasen

almost 4 years ago

After some amazing science of @IASLC #ACLC22, soaking up on the sun and sights of beautiful Nara, Japan. Lovely spending time with these amazing colleagues. @HwakeleeMD @karenkellymd #womeninthoraciconcology #lungcancer

triparnasen's tweet photo. After some amazing science of @IASLC #ACLC22, soaking up on the sun and sights of beautiful Nara, Japan. Lovely spending time with these amazing colleagues. @HwakeleeMD @karenkellymd #womeninthoraciconcology #lungcancer https://t.co/EGM6vpsLps

1

20

1

0

almost 4 years ago

Domo Arigatou Gozaimasu for joining the @IASLC #ACLC22. Conference chairs, Drs. @t_mitsudomi, Myung-Ju Ahn & James Yang share sincere gratitude to all delegates. Watch your email for the conference survey, and remember, sessions are available on-demand at https://t.co/ypODIUuEZ4

IASLC's tweet photo. Domo Arigatou Gozaimasu for joining the @IASLC #ACLC22. Conference chairs, Drs. @t_mitsudomi, Myung-Ju Ahn & James Yang share sincere gratitude to all delegates. Watch your email for the conference survey, and remember, sessions are available on-demand at https://t.co/ypODIUuEZ4 https://t.co/tShbqKZYpX

0

13

1

0

almost 4 years ago

Prof. The-Ying Chou presented heterogeneity between primary and metastatic sites in lung cancer referring to lineage plasticity as a background mechanism. #ACLC22 @IASLC #LCSM

HHorinouchi's tweet photo. Prof. The-Ying Chou presented heterogeneity between primary and metastatic sites in lung cancer referring to lineage plasticity as a background mechanism. #ACLC22 @IASLC #LCSM https://t.co/sCVMGRWZvv

0

3

1

0

almost 4 years ago

#MET Targeting Agents in a broad therapeutic landscape are the topic of the current presentation at #ACLC22 by @NReguart of Hospital Clinic Barcelona. She shares that targeted therapies are expanding, including TKIs, mABs, & ADCs in MET-dysregulated #NSCLC.

IASLC's tweet photo. #MET Targeting Agents in a broad therapeutic landscape are the topic of the current presentation at #ACLC22 by @NReguart of Hospital Clinic Barcelona. She shares that targeted therapies are expanding, including TKIs, mABs, & ADCs in MET-dysregulated #NSCLC. https://t.co/oIviNmS8F5

0

27

12

6

0

almost 4 years ago

Dr. Yoon-La Choi discusses tumor heterogeneity, transformation, and EMT as resistant mechanisms from a pathologist's point of view. #ACLC22 @IASLC #LCSM

HHorinouchi's tweet photo. Dr. Yoon-La Choi discusses tumor heterogeneity, transformation, and EMT as resistant mechanisms from a pathologist's point of view. #ACLC22 @IASLC #LCSM https://t.co/6s2wSRrsfo

0

5

4

1

0

almost 4 years ago

The FINAL session started! @triparnasen discusses lineage plasticity as a resistance mechanism to EGFR-targeted agents. Live Q&A covered SCLC/NE transformation not only in EGFR-TKIs but also ALK-TKIs and other treatments. #ACLC22 @IASLC #LCSM

HHorinouchi's tweet photo. The FINAL session started! @triparnasen discusses lineage plasticity as a resistance mechanism to EGFR-targeted agents. Live Q&A covered SCLC/NE transformation not only in EGFR-TKIs but also ALK-TKIs and other treatments. #ACLC22 @IASLC #LCSM https://t.co/uIlum1rIaf

0

5

3

1

0

almost 4 years ago

@triparnasen of @IcahnMountSinai presents Lineage Plasticity: SCLC Transformation as a Mechanism of Resistance at #ACLC22. She discusses lineage plasticity as a property of normal cells & cellular processes including transdifferentiation, dedifferentiation, & cell reprogramming.

IASLC's tweet photo. @triparnasen of @IcahnMountSinai presents Lineage Plasticity: SCLC Transformation as a Mechanism of Resistance at #ACLC22. She discusses lineage plasticity as a property of normal cells & cellular processes including transdifferentiation, dedifferentiation, & cell reprogramming. https://t.co/pg4zx41bWA

0

5

1

0